Cargando…

Challenges and opportunities for continued access to effective antibiotics - what role for the EU?

Large pharmaceutical companies have withdrawn from antibiotic R&D because of the high risk of failure and because antibiotics are less profitable than other areas; small and medium-sized enterprises (SMEs), which now drive antibiotic R&D, face difficulty securing funding for preclinical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, M, Panteli, D, Mossialos, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595735/
http://dx.doi.org/10.1093/eurpub/ckad160.640
_version_ 1785124938932289536
author Anderson, M
Panteli, D
Mossialos, E
author_facet Anderson, M
Panteli, D
Mossialos, E
author_sort Anderson, M
collection PubMed
description Large pharmaceutical companies have withdrawn from antibiotic R&D because of the high risk of failure and because antibiotics are less profitable than other areas; small and medium-sized enterprises (SMEs), which now drive antibiotic R&D, face difficulty securing funding for preclinical and early clinical trials, and risk significant economic losses when launching new antibiotics. To reinvigorate the antibiotic pipeline, a holistic package of aligned incentives is required, which takes into account public health factors, improves return of investment while supporting SMEs, and considers operational feasibility including potential political, regulatory, legislative, industry and financial hurdles. This presentation will highlight the main options in this area. Improving access to effective antibiotics requires both short- and longer-term measures. Reducing regulatory administrative hurdles, engaging in good procurement practice, increasing joint purchasing efforts, and considering payment models that de-link revenue from sales can keep older (but effective) antibiotics on the market by ensuring their economic viability. Strengthening the mapping of production capacities and product availability can improve transparency and identify options for action, while stockpiling and strengthening manufacturing capacities within and outside of the EU can boost the supply chain itself. Concrete measures and their feasibility will be briefly presented. The EU has a major role to play by supporting antibiotic R&D and engaging with other international efforts to promote optimal deployment of incentives, by ensuring that the lack of access to appropriate and effective antibiotics is recognized as a threat to global health security, and by building on its relationships with international institutions to act as a facilitator in the global space towards ensuring synergies among existing structures, communicating the cost of inaction, and supporting national and regional initiatives. SPEAKERS/PANELISTS: Danilo Lo Fo Wong Division of Country Health Programmes, WHO/Europe, Copenhagen, Denmark Malin Grape Ministry of Health and Social Affairs, Stockholm, Sweden Lieven De Raedt Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium
format Online
Article
Text
id pubmed-10595735
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105957352023-10-25 Challenges and opportunities for continued access to effective antibiotics - what role for the EU? Anderson, M Panteli, D Mossialos, E Eur J Public Health Parallel Programme Large pharmaceutical companies have withdrawn from antibiotic R&D because of the high risk of failure and because antibiotics are less profitable than other areas; small and medium-sized enterprises (SMEs), which now drive antibiotic R&D, face difficulty securing funding for preclinical and early clinical trials, and risk significant economic losses when launching new antibiotics. To reinvigorate the antibiotic pipeline, a holistic package of aligned incentives is required, which takes into account public health factors, improves return of investment while supporting SMEs, and considers operational feasibility including potential political, regulatory, legislative, industry and financial hurdles. This presentation will highlight the main options in this area. Improving access to effective antibiotics requires both short- and longer-term measures. Reducing regulatory administrative hurdles, engaging in good procurement practice, increasing joint purchasing efforts, and considering payment models that de-link revenue from sales can keep older (but effective) antibiotics on the market by ensuring their economic viability. Strengthening the mapping of production capacities and product availability can improve transparency and identify options for action, while stockpiling and strengthening manufacturing capacities within and outside of the EU can boost the supply chain itself. Concrete measures and their feasibility will be briefly presented. The EU has a major role to play by supporting antibiotic R&D and engaging with other international efforts to promote optimal deployment of incentives, by ensuring that the lack of access to appropriate and effective antibiotics is recognized as a threat to global health security, and by building on its relationships with international institutions to act as a facilitator in the global space towards ensuring synergies among existing structures, communicating the cost of inaction, and supporting national and regional initiatives. SPEAKERS/PANELISTS: Danilo Lo Fo Wong Division of Country Health Programmes, WHO/Europe, Copenhagen, Denmark Malin Grape Ministry of Health and Social Affairs, Stockholm, Sweden Lieven De Raedt Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium Oxford University Press 2023-10-24 /pmc/articles/PMC10595735/ http://dx.doi.org/10.1093/eurpub/ckad160.640 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Parallel Programme
Anderson, M
Panteli, D
Mossialos, E
Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
title Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
title_full Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
title_fullStr Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
title_full_unstemmed Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
title_short Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
title_sort challenges and opportunities for continued access to effective antibiotics - what role for the eu?
topic Parallel Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595735/
http://dx.doi.org/10.1093/eurpub/ckad160.640
work_keys_str_mv AT andersonm challengesandopportunitiesforcontinuedaccesstoeffectiveantibioticswhatrolefortheeu
AT pantelid challengesandopportunitiesforcontinuedaccesstoeffectiveantibioticswhatrolefortheeu
AT mossialose challengesandopportunitiesforcontinuedaccesstoeffectiveantibioticswhatrolefortheeu